Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

NCT02121639 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Placebo
DRUG: AZD5363

Sponsor

University Hospital Southampton NHS Foundation Trust

Collaborators

[object Object]
[object Object]